203 related articles for article (PubMed ID: 27816971)
1. The anti-tumor role of NK cells in vivo pre-activated and re-stimulated by interleukins in acute lymphoblastic leukemia.
Jin F; Lin H; Gao S; Hu Z; Zuo S; Sun L; Jin C; Li W; Yang Y
Oncotarget; 2016 Nov; 7(48):79187-79202. PubMed ID: 27816971
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity.
Satwani P; Bavishi S; Saha A; Zhao F; Ayello J; van de Ven C; Chu Y; Cairo MS
Cytotherapy; 2014 Oct; 16(10):1431-40. PubMed ID: 24856896
[TBL] [Abstract][Full Text] [Related]
3. TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells.
Lelaidier M; Dìaz-Rodriguez Y; Cordeau M; Cordeiro P; Haddad E; Herblot S; Duval M
Oncotarget; 2015 Oct; 6(30):29440-55. PubMed ID: 26320191
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic T lymphocytes and natural killer cells display impaired cytotoxic functions and reduced activation in patients with alcoholic hepatitis.
Støy S; Dige A; Sandahl TD; Laursen TL; Buus C; Hokland M; Vilstrup H
Am J Physiol Gastrointest Liver Physiol; 2015 Feb; 308(4):G269-76. PubMed ID: 25501547
[TBL] [Abstract][Full Text] [Related]
5. The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells.
Rettinger E; Kuçi S; Naumann I; Becker P; Kreyenberg H; Anzaghe M; Willasch A; Koehl U; Bug G; Ruthardt M; Klingebiel T; Fulda S; Bader P
Cytotherapy; 2012 Jan; 14(1):91-103. PubMed ID: 21973023
[TBL] [Abstract][Full Text] [Related]
6. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
Mani R; Rajgolikar G; Nunes J; Zapolnik K; Wasmuth R; Mo X; Byrd JC; Lee DA; Muthusamy N; Vasu S
Cytotherapy; 2020 Jul; 22(7):369-376. PubMed ID: 32303428
[TBL] [Abstract][Full Text] [Related]
7. In silico modeling identifies CD45 as a regulator of IL-2 synergy in the NKG2D-mediated activation of immature human NK cells.
Mukherjee S; Jensen H; Stewart W; Stewart D; Ray WC; Chen SY; Nolan GP; Lanier LL; Das J
Sci Signal; 2017 Jun; 10(485):. PubMed ID: 28655861
[TBL] [Abstract][Full Text] [Related]
8. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.
Romee R; Rosario M; Berrien-Elliott MM; Wagner JA; Jewell BA; Schappe T; Leong JW; Abdel-Latif S; Schneider SE; Willey S; Neal CC; Yu L; Oh ST; Lee YS; Mulder A; Claas F; Cooper MA; Fehniger TA
Sci Transl Med; 2016 Sep; 8(357):357ra123. PubMed ID: 27655849
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression.
Rossi LE; Avila DE; Spallanzani RG; Ziblat A; Fuertes MB; Lapyckyj L; Croci DO; Rabinovich GA; Domaica CI; Zwirner NW
J Leukoc Biol; 2012 Feb; 91(2):321-31. PubMed ID: 22124136
[TBL] [Abstract][Full Text] [Related]
10. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines.
Roda JM; Joshi T; Butchar JP; McAlees JW; Lehman A; Tridandapani S; Carson WE
Clin Cancer Res; 2007 Nov; 13(21):6419-28. PubMed ID: 17962339
[TBL] [Abstract][Full Text] [Related]
11. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells.
Chang YH; Connolly J; Shimasaki N; Mimura K; Kono K; Campana D
Cancer Res; 2013 Mar; 73(6):1777-86. PubMed ID: 23302231
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic applications: natural killer cells in the clinic.
Miller JS
Hematology Am Soc Hematol Educ Program; 2013; 2013():247-53. PubMed ID: 24319187
[TBL] [Abstract][Full Text] [Related]
13. Tumoral NKG2D alters cell cycle of acute myeloid leukemic cells and reduces NK cell-mediated immune surveillance.
Tang M; Acheampong DO; Wang Y; Xie W; Wang M; Zhang J
Immunol Res; 2016 Jun; 64(3):754-64. PubMed ID: 26740330
[TBL] [Abstract][Full Text] [Related]
14. MICA/IL-12: A novel bifunctional protein for killer cell activation.
Tietje A; Yang X; Yu X; Wei Y
Oncol Rep; 2017 Mar; 37(3):1889-1895. PubMed ID: 28098874
[TBL] [Abstract][Full Text] [Related]
15. Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-γ production in patients with active disease.
Hervier B; Beziat V; Haroche J; Mathian A; Lebon P; Ghillani-Dalbin P; Musset L; Debré P; Amoura Z; Vieillard V
Arthritis Rheum; 2011 Jun; 63(6):1698-706. PubMed ID: 21370226
[TBL] [Abstract][Full Text] [Related]
16. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
Jiang W; Zhang C; Tian Z; Zhang J
Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
[TBL] [Abstract][Full Text] [Related]
17. TNFα Augments Cytokine-Induced NK Cell IFNγ Production through TNFR2.
Almishri W; Santodomingo-Garzon T; Le T; Stack D; Mody CH; Swain MG
J Innate Immun; 2016; 8(6):617-629. PubMed ID: 27560480
[TBL] [Abstract][Full Text] [Related]
18. Retroviral gene transfer into primary human NK cells activated by IL-2 and K562 feeder cells expressing membrane-bound IL-21.
Streltsova MA; Barsov E; Erokhina SA; Kovalenko EI
J Immunol Methods; 2017 Nov; 450():90-94. PubMed ID: 28802832
[TBL] [Abstract][Full Text] [Related]
19. Critical role of the NKG2D receptor for NK cell-mediated control and immune escape of B-cell lymphoma.
Belting L; Hömberg N; Przewoznik M; Brenner C; Riedel T; Flatley A; Polić B; Busch DH; Röcken M; Mocikat R
Eur J Immunol; 2015 Sep; 45(9):2593-601. PubMed ID: 26151313
[TBL] [Abstract][Full Text] [Related]
20. IL32γ activates natural killer receptor-expressing innate immune cells to produce IFNγ via dendritic cell-derived IL12.
Lee SW; Park HJ; Lee KS; Park SH; Kim S; Jeon SH; Hong S
Biochem Biophys Res Commun; 2015 May; 461(1):86-94. PubMed ID: 25858316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
